Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer.
10.3760/cma.j.cn112139-20230510-00199
- Author:
Xu ZHANG
1
;
Yong Su MA
1
;
Xiao Dong TIAN
1
;
Yin Mo YANG
1
Author Information
1. Department of Hepatobiliary Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Neoadjuvant Therapy/methods*;
Pancreatic Neoplasms/pathology*
- From:
Chinese Journal of Surgery
2023;61(7):546-549
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is a highly malignant tumor. About 75% of patients with pancreatic cancer who underwent radical surgical resection will still experience postoperative recurrence. Neoadjuvant therapy could improve outcomes in patients with borderline resectable pancreatic cancer,has become a consensus;however it is still controversial in resectable pancreatic cancer. Limited high-quality randomized controlled trial studies support the routine initiation of neoadjuvant therapy in resectable pancreatic cancer. With the development of new technologies, such as next-generation sequencing, liquid biopsy, imaging omics, and organoids, patients are expected to benefit from the precision screening of potential candidates for neoadjuvant therapy and individualized treatment strategy.
